若生智能
Drug Database
TA

tamsulosin + tolterodine (Roliflo OD)

✓ Approved

Ranbaxy Laboratories Limited · ADRA1A · 小分子

什么是 tamsulosin + tolterodine？

tamsulosin + tolterodine 是一种小分子，由Ranbaxy Laboratories Limited研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Roliflo OD
公司Ranbaxy Laboratories Limited
药物类别小分子
分子靶点ADRA1A, CHRM1, CHRM2, CHRM3, CHRM4
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Ranbaxy Laboratories Limited

作用机制

分子靶点

tamsulosin + tolterodine 作用于 5 个分子靶点：

ADRA1Aadrenoceptor alpha 1A (ADRA1L1, ADRA1C)
CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (EGBRS, m3AChR)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tamsulosin + tolterodine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Renal and urinary disordersHypertonic bladder✓ Approved

相关研究文献

PubMedEuropean journal of obstetrics, gynecology, and reproductive biology2026-07-26

Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis.

Mohamed-Ahmed R R, Rantell A A, Robinson D D

Overactive bladder (OAB) is defined as 'urinary urgency with or without urinary urgency incontinence (UUI), usually associated with urinary frequency and/or nocturia, in the absence of urinary tract infection'. OAB is known to be a common disorder with a significant impact on quality of life. First line treatments include weight loss in those with a BMI > 30, bladder retraining and fluid advice. Pharmacotherapy treatment includes antimuscarinics and mirabegron, a beta 3 agonist. The National Institute of Clinical Excellence (NICE), has recently incorporated the use of a newer beta 3 agonist, vibegron, into its recommendations for the management of overactive bladder (OAB). There are no head-to-head studies which directly compare the efficacy of vibegron with mirabegron, an older beta 3 agonist. This network meta-analysis aims to compare the safety and efficacy of vibegron when compared to mirabegron and tolterodine, more longstanding treatments for OAB. A systematic review was conducted to identify phase III randomised controlled trials, for patients with idiopathic OAB, which compared mirabegron and/or vibegron and/or tolterodine. The primary outcome was the change from baseline in episodes of urinary urgency (UU). The secondary outcomes assessed were:The study was registered on PROSPERO (CRD 420250636077) and analysis was performed using MetaInsight. Of the 2,647 identified articles, five studies were deemed suitable to include in the network meta-analysis. Results for the primary outcome included 5,317 patients and demonstrated a greater improvement in UU episodes in the vibegron group, when compared to placebo, tolterodine and mirabegron. Vibegron also ranked favourably in reduction in episodes of UUI and improvement in maximum voided volume per void. Whereas mirabegron had the greater improvement in reduction in episodes of urinary frequency. The incidence of any adverse event was highest in the vibegron group. Tolterodine had the highest rate of hypertension and dry mouth. Constipation was highest in the vibegron group. However, it is important to note the large heterogeneity in definitions of adverse events as well as discrepancy in their reporting. Vibegron appears to rank more favourably for improvement in episodes of UU, UUI and maximum voided volume per void, when compared to mirabegron and tolterodine. Mirabegron ranks more favourably for improvement in episodes of urinary frequency over 24 h. Mirabegron is least likely to be associated with hypertension, although reporting of adverse events is non-standardised and therefore may not be comparable. This network meta-analysis does not account for other factors which may influence drug therapy choice i.e. contraindications, difficulties with swallowing and available treatment options.

PMID 42501511
阅读全文 →
PubMedGalen medical journal2026-07-25

Effect of Tamsulosin on Osteopontin Gene Expression in Preventing Ethylene Glycol-Induced Kidney Stone in Male Wistar Rats : Short title: Effect of Tamsulosin on Osteopontin Gene Expression.

Parvizrad Ramin R, Ghorbani Marghamlki Elahe E, Nikfar Somayeh S, Khalili Dermani Sara S

Tamsulosin, an α1-adrenergic receptor antagonist, has been proposed as a potential therapeutic agent against urolithiasis-induced renal damage. However, limited in vivo evidence exists regarding its renoprotective mechanisms. Forty male Wistar rats were randomly allocated into four groups (n=10/group): positive control, negative control (ethylene glycol-induced urolithiasis), prevention (tamsulosin administered simultaneously with ethylene glycol), and treatment (tamsulosin administered after model induction). Biochemical parameters including serum creatinine, urea, uric acid, calcium, and phosphorus were measured using rat-validated commercial kits (Pars Azmun, Iran). Normal ranges were defined based on published reference values. Gene expression was analyzed by qPCR using the 2^-ΔΔCt method. Study design and reporting followed the ARRIVE checklist. At day 30, the prevention group exhibited significantly lower serum creatinine (0.60 ± 0.08 mg/dL) compared to the negative control (0.98 ± 0.12 mg/dL, P0.01). Although urea levels were slightly higher in the prevention group (4.0 ± 0.7 mg/dL) versus the negative control (3.22 ± 0.6 mg/dL), the calculated BUN/creatinine ratio was significantly improved (46.7 vs. 33.0, P0.05). No significant changes were observed in serum calcium or phosphorus. Gene expression analysis showed upregulation of protective markers in the prevention group. In vivo findings on the beneficial effects of tamsulosin on the renal profile in ethylene glycol-induced urolithiasis illustrate its protective effects on the renal system through improvement of creatinine clearance and BUN/creatinine balance. This underscores its probable use as a protective therapeutic agent against renal injury of crystallization origin.

PMID 42499366
阅读全文 →
PubMedClinical pharmacology in drug development2026-07-20

Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended-Release Capsules in Healthy Chinese Volunteers: A Randomized, Open-Label, Crossover Study Under Fasting and Fed Conditions.

Du Lijie L, Wang Xiaolu X, Zhang Yi Y, Yang Jiamin J et al.

Tamsulosin hydrochloride is a long-acting, highly selective α1A receptor antagonist, primarily used to treat benign prostatic hyperplasia. It effectively alleviates lower urinary tract symptoms, including dysuria, nocturia, and urgency caused by prostate enlargement. This study aimed to evaluate the pharmacokinetics and bioequivalence of two tamsulosin extended-release capsules in Chinese volunteers under both fasting and fed conditions. A single-center, randomized, open-label, two-formulation, single-dose, two-period, two-way crossover design was used. A total of 64 healthy volunteers were enrolled, with 28 in the fasting group and 36 in the fed group. In the fasting group, each subject received a single dose of either the test or reference formulation in a randomized crossover design. In the fed group, volunteers consumed a high-fat meal 1 h before dosing. Blood samples were collected for up to 72 h post-dose, and plasma tamsulosin concentrations were measured using liquid chromatography-tandem mass spectrometry. The geometric mean ratios and 90% confidence intervals for key exposure metrics for both formulations under fasting and fed conditions were within the 0.8000-1.2500 bioequivalence range. Both formulations demonstrated bioequivalence under both conditions, and no severe adverse events were observed.

PMID 42474264
阅读全文 →
PubMedEuropean journal of pediatrics2026-07-20

Second- and third-line treatment options for refractory monosymptomatic enuresis in children: a scoping review.

Selvi Ismail I, Marco Beatriz Banuelos BB, Dönmez M İrfan Mİ, Baydilli Numan N et al.

Around one-third of patients with monosymptomatic nocturnal enuresis (MNE) do not respond to conventional first-line treatments. Although international guidelines outline second- and third-line treatment options, these recommendations may not fully address the needs of every case encountered in daily practice. Therefore, the question of which treatment strategy should be used for refractory cases remains unanswered. We conducted a scoping review (PROSPERO CRD420251171197) following PRISMA Extension for Scoping Reviews (PRISMA-ScR), searching the PubMed, Embase, Ovid MEDLINE, Scopus, Web of Science, Google Scholar, CINAHL and the Cochrane Library databases to identify all published reports of treatment for refractory MNE in paediatric patients up to March 2026. Eligible studies included randomized controlled trials and prospective or retrospective observational cohort studies written in English. The primary outcome was the number of wet nights (classified as complete, partial or no response according to the ICCS criteria). Secondary outcomes included a comparison of the efficacy of second- and third-line treatment options if enough data could be found. The Cochrane RoB 2 tool was used to assess the risk of bias in randomized clinical trials, and the Methodological Index for Non-Randomized Studies (MINORS) was used for non-randomized cohort studies. Following screening and eligibility assessment, 17 out of 2578 articles met the PICO inclusion criteria. The included studies enrolled a total of 1348 children and adolescents with mean ages ranging from approximately 8 to 17 years. Many of the second- or third-line treatments described in the literature were excluded due to incorrect methodology, study design or patient population. The results showed that, following first-line treatment, a combination of biofeedback, electrical nerve stimulations, anticholinergics (e.g. oxybutynin, tolterodine, solifenacin), β3-adrenoceptor agonists (e.g. vibegron), tricyclic antidepressants (e.g. imipramine) and selective serotonin reuptake inhibitor (e.g. fluoxetine) improved both partial response (PR) and complete response (CR) at varying rates across highly heterogeneous interventions and study populations. However, the evidence does not strongly support a treatment algorithm. Furthermore, reports on electro-acupuncture, furosemide, onabotulinumtoxin A injections or the herbal medicine 'shokenchuto' were considered unreliable for pure refractory MNE, despite improvements in PR and CR occurring at different rates. Conclusion: The question of which treatment strategy should be used for refractory cases remains unanswered due to a lack of sufficiently unbiased, prospective, randomized, controlled studies involving long-term follow-up. Some second- and third-line treatment options may improve PR and CR rates, despite the limited available evidence to support a treatment algorithm. However, further research is needed to confirm these benefits.

PMID 42472999
阅读全文 →
PubMedMedicine2026-07-18

A case report of primary prostate intravascular large B-cell lymphoma.

Yuan Fengju F, Liu Qian Q, Ding Wuwu W, Nie Jia J et al.

Primary intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that rarely affects the prostate. Its nonspecific clinical and laboratory features often lead to misdiagnosis as benign prostatic hyperplasia (BPH) or prostatitis, delaying appropriate treatment. We report a case of primary prostatic IVLBCL initially misdiagnosed as BPH, highlighting the diagnostic challenges and the importance of comprehensive pathological evaluation. A 75-year-old male presented with a 1-year history of a weakened urinary stream, dribbling, increased nocturia, and urinary urgency. Symptoms transiently improved with self-medication of the α1-blocker tamsulosin but later recurred. Histopathological examination revealed clusters of atypical tumor cells within the prostatic vasculature. Immunohistochemistry showed positivity for leukocyte common antigen, Vimentin, CD20, and CD79a, with a Ki-67 index > 90%. A final diagnosis of primary intravascular large B-cell lymphoma of the prostate was established. Following diagnosis, the patient and his family declined any antitumor therapy (including chemotherapy) and opted for best supportive care and were discharged against medical advice. The patient died 5 months after diagnosis without receiving any subsequent antitumor therapy. Prostatic IVLBCL is a diagnostic mimic of BPH and requires a high index of suspicion. Immunohistochemistry and molecular studies are essential for accurate diagnosis. Early recognition and appropriate chemotherapy can improve outcomes in this rare malignancy.

PMID 42470066
阅读全文 →
PubMedInternational journal of clinical and experimental pathology2026-07-17

Tamsulosin versus placebo for medical expulsive therapy in ureteral calculi: a systematic review and meta-analysis of randomized controlled trials.

Yang Jinxin J, Yang Jin J, Zhang Hanchao H, Hu Haifeng H et al.

Ureteral calculi are a common cause of emergency department visits worldwide. Although small stones often pass spontaneously, medical expulsive therapy is frequently used to facilitate stone clearance and reduce the need for surgical intervention. Tamsulosin, an α1-adrenergic receptor antagonist, is commonly prescribed for this purpose, but its efficacy compared with placebo remains uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials comparing tamsulosin with placebo in patients with ureteral calculi. A comprehensive search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed from database inception through April 2025. The primary outcome was the stone expulsion rate, and secondary outcomes included time to expulsion and the incidence of adverse events. Pooled estimates were calculated as risk ratios or mean differences with 95 percent confidence intervals, using a random-effects model. A total of 42 randomized controlled trials involving 7,117 patients met the inclusion criteria. Compared with placebo, tamsulosin significantly increased the stone expulsion rate (risk ratio 1.42, 95 percent confidence interval 1.29 to 1.56, P < 0.001) and shortened the time to expulsion by an average of 3.04 days (95 percent confidence interval 2.28 to 3.81 days, P < 0.00001). The overall incidence of adverse events did not differ significantly between groups, although subgroup analysis indicated a lower risk of moderate to severe complications with tamsulosin (risk ratio 0.35, 95 percent confidence interval 0.22 to 0.98, P < 0.0001). Substantial heterogeneity was observed across outcomes. In conclusion, tamsulosin improves stone expulsion and reduces clearance time without increasing overall adverse events. However, given the considerable heterogeneity among studies, these findings should be interpreted with caution. Further high-quality, large-scale trials are needed to confirm the benefits of tamsulosin and to identify patient subgroups most likely to benefit from therapy.

PMID 42466212
阅读全文 →

注册免费账户还可查看另外 3327 篇文献

免费注册查看全部文献 →

了解更多tamsulosin + tolterodine